Novo Nordisk Slashes GLP-1 Prices 70%: What It Means for Patients

In early 2026, Novo Nordisk announced it would slash US list prices for its GLP-1 medications by up to 70% — the largest single price reduction in the GLP-1 drug class's history. This brings the net price of Wegovy from approximately $1,350/month to closer to $400/month, and reduces Ozempic pricing proportionally.

What prompted the cut. This was not an act of corporate generosity — it was a strategic necessity driven by multiple converging pressures. Competition from Eli Lilly's tirzepatide (Zepbound), which was gaining market share rapidly, created direct pricing pressure. Political pressure on drug pricing intensified with both parties in Congress targeting GLP-1 costs. Generic semaglutide is approaching in international markets as patents expire in 8+ countries in 2026, threatening Novo's global pricing power. And Novo needed to expand the total patient population who could afford treatment to maintain revenue growth as the per-unit price inevitably declined.

The scope of the reduction. The price cut applies across Novo's GLP-1 portfolio: Wegovy (semaglutide 2.4mg for weight management), Ozempic (semaglutide 1mg for type 2 diabetes), and the new oral Wegovy formulation. The reduction is to list prices — what insurers and pharmacy benefit managers negotiate from — which does not always translate directly to patient-facing costs.

A preemptive move. Industry analysts characterize this as a preemptive price floor strategy. By establishing a lower price point before generic competition arrives, Novo makes generic entry less attractive (generics need to price significantly below the brand to gain market share, and a lower brand price narrows that gap). It also makes compounded semaglutide (typically $200-400/month) less price-competitive, potentially reducing the appeal of compounding pharmacy alternatives.

The practical impact of Novo's price cuts on what patients actually pay depends heavily on their insurance status, formulary placement, and access to patient assistance programs.

Commercially insured patients. For patients with commercial insurance (employer-sponsored or individual market plans), the impact may be modest. Many were already using Novo Nordisk's savings card program, which reduced out-of-pocket costs to $25-$100/month. The list price reduction may improve formulary placement and reduce prior authorization barriers, but direct copay impact is often filtered through the insurer's benefit design.

Medicare patients. Medicare Part D patients may see more meaningful cost reductions, as the Inflation Reduction Act's out-of-pocket cap and the lower list price interact to reduce patient costs. However, Medicare coverage of weight management drugs (as opposed to diabetes drugs) remains inconsistent and varies by plan.

Uninsured and self-pay patients. For patients paying out of pocket, the reduction from $1,350 to approximately $400/month is significant but still substantial. At $400/month ($4,800/year), semaglutide remains a major expense for most households. Novo's patient assistance programs can reduce costs further for income-qualified patients, but navigating these programs can be complex.

Competitive comparison. Eli Lilly's LillyDirect program offers Zepbound at $299/month for the 2.5mg starting dose, creating a clear price comparison point. At $400/month for Wegovy versus $299/month for Zepbound's starting dose, tirzepatide has a modest price advantage on the self-pay market — combined with superior efficacy data, this creates a challenging competitive dynamic for Novo.

Revenue outlook. Despite lower per-unit prices, financial analysts project that semaglutide revenue could hold steady or even grow in 2026. The logic: lower prices will significantly expand the total addressable patient population (currently estimated at less than 10% of eligible patients), and the volume growth is expected to offset per-unit revenue decline. This is the standard pharmaceutical playbook when facing the "volume vs. price" tradeoff.